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Abstract
Fluorescent magnetic nanoparticles exhibit great application prospects in biomedical engineering. Herein, we
reported the effects of hydrophilic silica-coated CdTe quantum dots and magnetic nanoparticles (FMNPs) on
human embryonic kidney 293 (HEK293) cells and mice with the aim of investigating their biocompatibility. FMNPs
with 150 nm in diameter were prepared, and characterized by high-resolution transmission electron microscopy
and photoluminescence (PL) spectra and magnetometer. HEK293 cells were cultured with different doses of FMNPs
(20, 50, and 100μ g/ml) for 1-4 days. Cell viability and adhesion ability were analyzed by CCK8 method and
Western blotting. 30 mice were randomly divided into three groups, and were, respectively, injected via tail vein
with 20, 60, and 100 μg FMNPs, and then were, respectively, raised for 1, 7, and 30 days, then their lifespan,
important organs, and blood biochemical parameters were analyzed. Results show that the prepared water-soluble
FMNPs had high fluorescent and magnetic properties, less than 50 μg/ml of FMNPs exhibited good
biocompatibility to HEK293 cells, the cell viability, and adhesion ability were similar to the control HEK293 cells.
FMNPs primarily accumulated in those organs such as lung, liver, and spleen. Lung exposed to FMNPs displayed a
dose-dependent inflammatory response, blood biochemical parameters such as white blood cell count (WBC),
alanine aminotransferase (ALT), and aspartate aminotransferase (AST), displayed significant increase when the
FMNPs were injected into mice at dose of 100μg. In conclusion, FMNPs exhibit good biocompatibility to cells
under the dose of less than 50 μg/ml, and to mice under the dose of less than 2mg/kg body weight. The FMNPs’
biocompatibility must be considered when FMNPs are used for in vivo diagnosis and therapy.
Introduction
Up to date, nanomaterials and nanotechnology have
shown great potentials in disease diagnosis and therapy
[1-7]. For example, a broad range of nanoscale inorganic
particles including magnetic nanoparticles (MNPs) and
quantum dots (QDs) have been systematically investi-
gated for their unique physical, chemical properties, and
their potential application in bio-detection, molecular
imaging, and photothermal therapy of tumors [8-16].
Especially, MNPs have been used for magnetic reso-
nance imaging (MRI), gene delivery, cell separation and
cancer hyperthermia [17-19], and magnetic targeting,
which provides an alternative method for targeted drug
delivery systems to the desired location [20-22]. Up to
date, QDs have been subjected to intensive investiga-
tions due to their unique properties and potential appli-
cation prospect [23,24]. Several methods have been
developed to synthesize water-soluble QDs for use in
biological relevant studies [25,26]. For example, QDs
have been used successfully in cellular imaging [27],
immunoassays [28], DNA hybridization [29], optical bar-
coding [30], and drug carrier [31]. QDs provide a new
functional platform for bioanalytical sciences and bio-
medical engineering.
In our previous study, we successfully prepared
fluorescent MNPs composed of silica-coated CdTe
QDs and magnetic nanoparticles (FMNPs), and used
as-prepared FMNPs to label biomolecules for tumor
imaging and hyperthermia therapy, and actively inves-
tigated their potential applications in bio-labeling,
bio-separation, immunoassay, target imaging, and
pathogenic detection [32-36]. Up to date, there were
many reports which closely associated with preparation
of fluorescent MNPs and their applications in
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biomedical engineering [37-47]. However, few report is
closely associated with biocompatibility of fluorescent
MNPs [48,49]. With the rapid development of nano-
technology, nanomaterials’ biosafety has attracted more
and more attention [50-56].
Herein, we investigated the effects of hydrophilic silica-
coated CdTe QDs and magnetic nanoparticles (FMNPs)
on human embryonic kidney 293 cells (HEK293) and
mice with the aim of evaluating biocompatibility of pre-
pared FMNPs. Our results showed that prepared FMNPs
exhibited good biocompatibility under a special dose, and
display great potential in applications such as in vivo
molecular imaging, and hyperthermia therapy as well as
in vitro pathogen separation and detection.
Experimental
Synthesis and characterization of FMNPs
FMNPs were prepared using improved method based on
our previous reported method [40]. First, Fe3O4@Polys-
tyrene (Fe3O4/PS) nanospheres were prepared according
to Ref. [41], CdTe QDs were prepared according to our
previous method [32], then CdTe QDs were modified to
the surface of Fe3O4@Polystyrene (Fe3O4/PS) nano-
spheres, resultant CdTe QDs-covered MNPs were modi-
fied with silica shell using reverse microemulsion
method, finally prepared FMNPs were washed with PBS
(pH 7.4), isolated, and then saved for usage. Prepared
FMNPs were characterized using scanning electron
microscopy (SEM), high-resolution transmission elec-
tron microscopy (TEM, JEOL JEM2010, at 200 kV), the
photoluminescence (PL) spectra (Perkin Elmer LS 55
spectrofluorimeter), and superconducting quantum
interference device (SQUID) magnetometer (Quantum
Design, PPMS-9T).
Observation of cells incubated with FMNPs
HEK293 cells were seeded on cover slips for overnight,
and were treated with medium with FMNPs (50 μg/ml)
for 3 h. Then, the cells were rinsed with distilled water
and stained with Prussian blue according to protocol.
The HEK 293 cells were not treated with medium with
FMNPs as the control. Then, the samples were attached
to glass plates using mounting medium, and then were
observed under an optical microscope (Olympus IX71).
Fluorescent microscopy observation
HEK293 cells incubated with FMNPs (50 μg/ml) were
collected, and fixed with 2.5% glutaraldehyde for 30
min, then, were incubated with 1 mM Hoechst 33258 in
PBS (pH 7.4) for 5 min, and then were washed with
PBS (pH 7.4) for three times, finally these cells were
observed under fluorescence microscope (NIKON
TS100-F).
Flow cytometry analysis
HEK293 cells were treated without or with 20 μg/ml of
FMNPs for 24 h, and were collected. After washing with
PBS (pH 7.4), these cells were fixed with 70% ethanol/
PBS for 30 min on ice. Approximately, 4 × 105 cells
were centrifuged and re-suspended with PBS (pH 7.4),
and then were analyzed by Calibur Flow Cytometers
(BD Biosciences, Sunnydale, CA), the number of cells
labeled with FMNPs were counted on.
TEM observation of endocytosis course of FMNPs
HEK 293 cells were treated with 50 μg/ml FMNPs for
24 h. Then these cells were collected and fixed with
2.5% glutaraldehyde solution, and then embedded with
epoxy resin, finally, these cells were made into the ultra-
thin slices, and then observed with TEM.
Effects of FMNPs on HEK 293 cells viability and
proliferation assay
Effects of FMNPs on proliferation and viability of
HEK293 cells were analyzed using Cell Counting Kit-8
(CCK8) assay. HEK293 cells were cultured in the 96-
well microplate at the concentration of 5000 cells per
well and incubated in a humidified 5% CO2 balanced air
incubator at 37°C for 24 h. Except for control wells, the
remaining wells were added into medium with FMNPs,
final concentrations were, respectively, 20, 50, and 100
μg/ml, then those cells were continued to culture for 1-
4 days, then, the ODs were measured using the Thermo
multiskan MK3 ELISA plate reader according to the
protocol of CCK8 assay kit, and calculated the survival
rate of cells. The survival rate of cells can be calculated
by the following equation:
Cell viability (%) = optical density (OD)of the treated cells/
ODof the non − treated cells× 100
Detection of cell adhesion ability
Six-well plates were coated with fibrinogen (5 μg/ml)
and vitronectin (1.5 μg/ml) in Dulbecco’s Phosphate
Buffered Saline (DPBS). HEK293 cells were harvested,
washed for three times with serum-free minimal essen-
tial medium with Eargle ’s salt, and resuspended in
attachment solution (calcium- and magnesium-free
Hanks’ balanced salt solution, 20 mM HEPES, 1 mg/ml
heat-inactivated BSA, 1 mM CaCl2 and 1 mM MgCl2).
Except for the control cells without treated with
FMNPs, each well was added 1 × 104 HEK 293 cells and
cultured for 1-4 days with FMNPs at different concen-
trations: 20, 50, and 100 μg/ml, unattached cells were
washed with Hanks’ balanced salt solution. The num-
bers of remaining attached cells after centrifugation
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were quantified spectrophotometrically at 405 nm for
three times [55].
Cell adhesion ability (%) = the number of FMNPs− treated adhesive cells /
the number of control adhesive cells.
Western blotting analysis of adhesive proteins
HEK293 cells were, respectively, incubated with FMNPs
(20, 50, and 100 μg/ml) for 4 days, then they were col-
lected and lysed in protein lysis buffer. Equal amounts of
sample lysates were separated by sodium dodecylsulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and elec-
trophoretically transferred onto polyvinylidene difluoride
(PVDF) membranes (Millipore). The membrane was
blocked with 0.1% BSA in Tris-Buffered Saline Tween-20
(TBST) buffer, and incubated overnight at 4°C with speci-
fic primary antibodies such as anti-fibronectin monoclonal
antibody, anti-cyclin D3 antibody, anti-laminin antibody,
anti-FAK antibody, and anti-b-actin antibody. Subse-
quently, the membrane was washed with TBST buffer and
incubated with horseradish peroxidase-conjugated second-
ary antibodies. Enhanced chemiluminescence kits were
used (Amersham, ECL kits) [55].
Effects of FMNPs on mice
All animal experiments were performed in compliance
with the local ethics committee. Kunming mice (female
28-30 g, 4-5 weeks old) were obtained from the Shang-
hai LAC Laboratory Animal Co. Ltd., Chinese Academy
of Sciences (Shanghai, China) and housed in positive-
pressure air-conditioned units (25°C, 50% relative
humidity) on a 12:12-h light/dark cycle. The mice were
allowed to acclimate at this facility for 1 week before
being used in the experiment. All mice were divided
into three test groups with FMNPs (20, 60, and 100 μg),
and one control group (0 μg), and each mouse was
injected with the suspension with FMNPs via tail vein.
Those mice were, respectively, killed at No. 1-, 7- and
30-day post-injection, their organs such as heart, liver,
spleen, stomach, kidneys, lungs, and brain were collected
immediately. Then, those organs were fixed with 10%
formaldehyde, embedded in paraffin, were cut into
20-μm section, stained with hematoxylin and eosin, and
were observed by light microscopy. Three mice without
FMNPs treatment were used as control.
After mice treated with different doses of FMNPs (20, 60,
and 100 μg) for 1, 7, and 30 days, the blood were, respec-
tively, collected in potassium EDTA collection tubes using
a standard saphenous vein blood collection technique and
were analyzed for standard hematology markers: red blood
cell count (RBC), hemoglobin, hematocrit, mean corpuscu-
lar volume (MCV), mean corpuscular hemoglobin (MCH),
mean corpuscular hemoglobin concentration (MCHC),
platelet count, and white blood cell count (WBC). In order
to separate serum, blood samples were centrifuged twice at
3000 rpm for 10 min. Liver function was evaluated with
serum levels of total bilirubin levels (TBIL), alanine amino-
transferase (ALT), aspartate aminotransferase (AST), and
alkalinephosphatase (ALP). Nephrotoxicity was determined
by blood urea nitrogen (BUN) and creatinine (Cr). The
enzyme of lactate dehydrogenase (LDH) was assayed for
evaluating cardiac damage. Albumin (ALB) was assayed as
one parameter of damage of tissue or inflammation. These
parameters were all assayed using a Hitachi 7600 Auto-
matic Biochemical Autoanalyzer.
Statistical analysis
Each experiment was repeated three times in duplicate.
The results were presented as mean ± SD. Statistical dif-
ferences were evaluated using the t test and considered
significance at P< 0.05.
Results and discussion
Characterization of FMNPs
It is well known that MNPs can quench the fluorescent
signal of QDs, which is because MNPs can absorb
strongly the light emitted by QDs [42-44]. How to
obtain FMNPs with high fluorescent signal and mag-
netic intensity is a great technical challenge. In order to
prepare high performance of FMNPs, we improved the
synthesis method based on our previous method [32].
We selected Fe3O4/PS nanospheres to replace Fe3O4
nanoparticles with the aim of reducing the QDs’ fluores-
cence quenching caused by MNPs. The main procedure
is as follows: first, fully mix Fe3O4/PS (100 nm average
diameter) with CdTe QDs (3.5 nm average diameter)
according to the ratio of 10:1, secondly, use ammonia-
catalyzed hydrolysis method of tetraethyl orthosilicate
(TEOS) to prepare silica-covered on the nano-compo-
sites composed of Fe3O4/PS MNPs and CdTe QDs. We
optimized the FMNPs’ reaction condition based on
reverse micro-emulsion method through the Ternary
phase diagram [48-50], finally obtained hydrophilic
silica-coated CdTe QDs and MNPs with high fluores-
cent signal and magnetic intensity.
As shown in Figure 1a, through measuring the conduc-
tivity and transparency of reverse micro-emulsion varia-
tions [48], we discovered that, under 6:4 of the surfactant
(Triton X-100 and N-hexanol) and oil phase (cyclohex-
ane), the micro-emulsion’s maximal water solubilization
had the wide range, thus, under above reaction condition,
we can prepare the ideal FMNPs. Figure 1b showed
the SEM images of FMNPs, prepared FMNPs were
sphere with the average diameter of 150 nm. As shown
in Figure 1c, d, FMNPs are mono-dispersed nano-com-
posites composed of silica shells and Fe3O4/PS and QDs,
the silica-shell thickness is almost 30 nm, the whole
nanocomposites is almost 150 nm in diameter.
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As shown in Figure 2a, FMNPs showed different colors
under UV radiation, which is because we used different
sizes of CdTe QDs in the course of preparing FMNPs.
FMNPs were assembled and the solution became trans-
parent under the external magnetic field (top), after
removal of the external magnetic field, the aggregations
were rapidly redispersed evenly (bottom). As shown in
Figure 2b, the PL spectra of FMNPs showed that the
emission peak of prepared FMNPs was symmetric with a
5 nm blue shift compared with pure QDs. As shown in
Figure 2c, the magnetic hysteresis curve of prepared
FMNPs clearly indicated that prepared FMNPs owned
superparamagnetic property at room temperature with a
saturation magnetization (Ms) value of 4.0 emu g
-1. This
Ms value was lower than the saturation magnetization of
Fe3O4/PS (Ms = 38 emu·g
-1). The reduction of Ms Value
is attributed to the lower density of the magnetic compo-
nent in prepared FMNPs.
Localization of FMNPs inside cells
As shown in Figure 3a, FMNPs were endocytosed by
HEK293 cells, and located in the cytoplasm around
nucleus, FMNPs exhibited red color (Figure 3a), and cell
nucleuses exhibited blue color (Figure 3b), Figure 3c is
the combined image of red and blue colors. The similar
results were also confirmed by Prussian blue staining
method (Figure 3d), and TEM imaging (Figure 3e).
According to our observation, the HEK293 cells first
formed pseudopodia, then wrapped FMNPs into cyto-
plasm, FMNPs mainly located inside lysosome and
endosome [48,49]. Within cultured time, we did not
observe that FMNPs were exited out of cells, FMNPs
coexisted with cells well.
As shown in Figure 4, FCM analysis result showed that,
HEK293 cells were treated with 20 μg/ml FMNPs for 24 h,
the number of cells with FMNPs was 43.52% (right), the
number of positive cells in control group is 0% (left).
Figure 1 Characterization of FMNPs. (a) Ternary phase diagram of W/O reverse micro-emulsion reaction system; (b) SEM image of FMNPs,
FMNPs were sphere with 150 nm in diameter; (c) TEM image exhibited that the FMNPs are mono-dispersed, silica shells covered Fe3O4/PS and
QDs; and (d) the magnified image of the FMNPs presented a silica-shell thickness of 30 nm on average, and the mean total diameter was 150 nm.
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Effects of FMNPs on cell viability
As shown in Figure 5, HEK293 cells were cultured with
50 μg/ml FMNPs for 72 h, HEK293 cells became round,
and floated, apoptotic cells formed nodular structure
encapsulated with FMNPs. When HEK293 cells were
cultured with 100 μg/ml FMNPs for 72 h, these cells
exhibited typical apoptosis features such as membrane
vesicles, nucleus condensation, fragmentation, and apop-
totic body formation. Within 50 μg/ml FMNPs in med-
ium, HEK 293 cells grew well, FMNPs did not show
toxic sign.
Regarding the effects of FMNPs on HEK 293 cells, as
shown in Figure 6, FMNPs affected the growth of
HEK293 cells in time- and dose-dependent means, simi-
lar to our previous report [5,55]. FMNPs of 20 μg/ml in
medium exhibited no toxicity to cells, the cell survival
rate increased with the culture days increased. When the
dose of FMNPs in medium reach or overrun 50 μg/ml,
FMNPs exhibited low cytotoxicity to HEK 293 cells, the
cell growth became slow. When the dose of FMNPs
reach or overrun 100 μg/ml in medium, cell survival rate
significantly decreased as the culture days increased.
Thus, we consider that FMNPs exhibited good
biocompatibility to HEK 293 cells within the dose of 50
μg/ml in medium.
Effects of FMNPs on cell adhesion
The adhesive ability of FMNPs-treated HEK293 cells
were evaluated by centrifugation method. As shown in
Figure 7a, the adhesion ability of HEK293 cells decreased
gradually as the amount of FMNPs and culture days
increased. As shown in Figure 7b, Western blotting ana-
lysis showed that the adhesive proteins such as laminin,
fibronectin, FAK, and cell cycle protein cyclin D3 exhib-
ited gradual down-regulation expression as the con-
centration of FMNPs increased. The b-actin protein
expression as the control, kept unchanged in each case.
These results showed that FMNPs can induce adhesion-
associated proteins exhibit down-regulation expression,
leading to thinning of cell basement membrane and
decrease of the cell adhesion ability, finally resulting in
cellular apoptosis or death.
Effects of FMNPs on lifespan of mice
Regarding the effects of FMNPs on lifespan of mice, we
used tail vein injection pathway to evaluate the in vivo
Figure 2 The fluorescence intensity and saturation magnetization of the FMNPs. (a) Images of FMNPs under UV irradiation with (top) and
without (bottom) an external magnetic field; (b) PL spectra of different emission wavelength of CdTe QDs and FMNPs; (c) field-dependent
magnetization curve of FMNPs at room temperature.
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Figure 3 Location of the FMNPs on HEK293 cell: (a) the microscopy image of FMNPs presenting red fluorescence inside of the HEK293 cells;
(b) the microscopy image of HEK293 cells nuclear counterstaining with Hoechst 33258; (c) image of combining the blue nuclear and red
FMNPs; (d) the microscopy image of HEK293 cells’ Prussian blue staining; and (e) TEM image of microstructure of HEK293 cell treated with 50
μg/ml FMNPs for 24 h.
Figure 4 Flow cytometry analysis the amount of HEK293 cells labeled with FMNPs.
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toxicity of FMNPs. The mice were injected with 200 μl
of FMNPs with the concentrations of 0 mg/ml (control
group), 0.1 mg/ml (low dose group, LD), 0.3 mg/ml
(medium dose group, MD), and 0.5 mg/ml (high dose
group, HD). After cultured for 1 day, 1 week, and 1
month, the mice were killed by the method of cervical
vertebra displace, and then used histopathology to eval-
uate inflammation degree of the mouse organs.
When the mice were injected with FMNPs of 20 and
60 μg, mice did not die, also did not show obvious clini-
cal toxic signs, and then the body weight also increased
accordingly. However, 3 of 9 mice injected with 100 μg
Figure 5 Effect of FMNPs on HEK293 cells morphology (magnification = ×400), morphology of HEK293 cells cultured with different
concentrations of FMNPs on different days, showing cells become round and floating with apoptotic characteristics.
Figure 6 Effect of FMNPs on survival rate of HEK293 cells, HEK293 cells viability measured by CCK8 assay and the percentage of cell
viability was calculated as a ratio of OD of FMNPs-treated cells and control cells.
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FMNPs died (0 in the 1-day group, 2/3 in the 7-day
group and 1/3 in the 30-day group). All mice deaths
occurred in No. 1-30days after injection of the FMNPs.
Before death, mice appeared lethargy, inactivity, and
body-weight losses. In addition, the mice treated with
100 μg of FMNPs for 1day appeared weakness, and lost
10% of body weights within first week, these symptoms
disappeared after 1week, mice could eat food normally,
and their body-weight increased.
Effects of FMNPs on important organs
We also investigated the effects of FMNPs on impor-
tant organs of mice. The pathological analysis showed
that the FMNPs primarily accumulated in the lung,
liver, and spleen, and pulmonary exposures to FMNPs
exhibited a dose-dependent organ inflammatory
response characterized by neutrophils and foamy
alveolar macrophage accumulation. when the dose of
injected FMNPs were lower than 60 μg, important
organs did not exhibit obvious inflammatory response,
conversely, when the dose of FMNPs overrun 60 μg,
important organs appeared obvious morphological
changes. Figures 8 and 9 showed that the morphologi-
cal changes of different organs from mice exposed to
different doses of FMNPs for 7 days, which clearly
showed that some important organs such as liver,
spleen, etc. appeared a dose-dependent series of granu-
lomas. With the increase of dose of FMNPs, the toxi-
city reaction of mice became more and more severe.
FMNPs induced mice to appear dose-dependent
epithelioid granulomas and interstitial inflammation,
large amount of inflammation cells infiltrated in lung
alveolus interstitium, the alveolar septa became thicker
and some lung alveoli were cracked.
In order to observe the high accumulation levels and
to assess the biological effects of FMNPs in mice
organs, ultrathin sections were prepared from the har-
vested mice lungs and liver for TEM imaging. Figure
10 showed the TEM images of the ultrastructural fea-
tures of the lung (Figure 10a) and spleen (Figure 10b)
tissues exposed to FMNPs. The FMNPs still remained
in the lungs after 30 days, some in capillary vessel and
some in cytoplasmic vacuoles of lung tissues. There
were a lot of inflammation cell appeared in the wall of
lung vacuole, such as multinuclear giant cells and acid-
ophilic cells. The ultrastructural features of most cells
appeared pathological changes. Thus, large dose of
FMNPs can cause important organs of mice appeared
obvious chronic toxic responses, low dose of FMNPs
(less than 60 μg) almost did not cause obvious toxic
signs.
Regarding the biodistribution of FMNPs in mice, as
we observed, FMNPs mainly located in lung, liver, and
spleen, no FMNPs was found in the brain tissues, which
highly suggest that FMNPs cannot get through blood-
brain barrier. Few FMNPs was observed in kidney of
mice, which highly suggest that FMNPs is very difficult
to be exited out by pathway of kidney, we speculate that
FMNPs are mainly expelled out by liver secretion into
bile tract system as shown in Figure 10c.
Effects of FMNPs on blood biochemical parameters
We collected the blood samples post-injection on No. 1,
7 and 30 days and analyzed the blood markers. The
Figure 7 Effects of FMNPs on cell adhesion ability and adhesive proteins. (a) The adhesion ability of HEK293 cells treated with FMNPs.
(b) Western blot analysis of the effect of FMNPs on the expressions of cyclin D3, laminin, FAK, fibronectin, and b-actin. Lanes 1, 2, 3, and 4 are
the protein expressions at FMNPs concentrations of 0, 20, 50, and 100 μg/ml, respectively.
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hematological results indicated that measured factors
were within normal ranges and there were not signifi-
cantly different between groups with low and middle
doses (20, 60 μg) and control (0 μg). Animals treated
with higher dose (100 μg) showed significant increases
in WBCs (P< 0.05) (Figure 11a), it illustrated that the
higher dose (100 μg) of FMNPs could cause the inflam-
mation reaction of mice.
Blood biochemical parameters that reflect the hepatic
function and renal function were further investigated
on No. 1, 7 and 30 days. Serum ALT or AST levels
were increased with FMNPs’ administration at 100 μg,
while no increase was observed at 20 and 60 μg
(Figure 11b, c). It illustrated that higher dose (100 μg,
2mg/kg body weight) of FMNPs influence the hepatic
functions of mice. There were no significant changes
Figure 8 The light micrograph of different organs about mice exposed to different dose FMNPs for 7 days. (a) 20 μg, (b) 60 μg, and (c)
100 μg (magnification=×400).
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for renal functions parameters such as urea nitrogen
and others biochemical indexes after administration of
FMNPs.
In this study, we also investigated the effects of as-pre-
pared FMNPs on human fibroblast cells, gastric cancer
MGC803 cells, and gastric mucous GES-1 cells, and
obtained similar results, therefore, in this article, we did
not display all data.
Conclusion
FMNPs were successfully prepared by improved reverse
micro-emulsion method. The prepared FMNPs possess
Figure 9 The light micrograph of different organs from mice exposed to FMNPs of 60 μg at different exposure times. (a) 1day,
(b) 7days, and (c) 30days (magnification=×400).
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strong fluorescent signal and high magnetization satura-
tion intensity. FMNPs exhibited good biocompatibility to
human normal cells with the concentration of 50 μg/ml
FMNPs in cell medium, and to mice injected within the
dose of 60 μg(2mg/kg. body weight) FMNPs. Conversely,
when the dose of FMNPs reach or overrun 100 μg/ml in
cell medium, or 60 μg to be injected into mice, cells and
mice exhibited obvious toxic signs. Therefore, we strongly
suggest that FMNPs can be safely used for cell labeling
and in vivo tracking and imaging within 60 μg, and do not
affect cell function and mice lifespan. Further work will
focus on the surface modification of prepared FMNPs to
enhance their biocompatibility. We believe that these pre-
pared FMNPs have great potential in applications such as
bio-labeling, bio-separation, immunoassay, in vivo target-
ing imaging and pathogenic detections.
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